November 2024

SkIN Canada Skin Investigation Network of Canada

E-bulletin

Funded by

Institute of Musculoskeletal Health and Arthritis

SkIN Canada News

Save the Date: Canadian Skin Research Conference

June 22-23, 2025 in Halifax 

Team Development Award Recipients

Dr. Irene Lara-Corrales (2022 Recipient)

Dr. Irene Lara-Corrales is a Professor of Pediatrics at the University of Toronto and a staff physician in Pediatric Dermatology at the Hospital for Sick Children in Toronto, Canada.  She completed her medical training and pediatric residency at the University of Costa Rica, in San Jose, Costa Rica and her pediatric dermatology training at the Hospital for Sick Children. She obtained a Master in Science degree from the University of Toronto. She is involved in numerous clinical and research endeavours, as well as in teaching commitments. She co-directs the Genodermatoses, Epidermolysis Bullosa, Vascular Tumors, Hidradenitis suppurativa and Café-au-Lait Screening clinics at SickKids and is part of the multidisciplinary clinic for the management of complex vascular anomalies. She is actively involved in the Pedriatric Dermatology Research Alliance (PeDRA) and Co-Chairs the Acne and Hidradenitis suppurativa study group. Her research interests include genodermatoses, inflammatory diseases and vascular anomalies. She is the current research lead for the Division of Dermatology at SickKids”. 

Title: A Canadian Interdisciplinary collaboration for Hidradenitis Suppurativa patients.

Lay Abstract: Hidradenitis Suppurativa (HS) is a chronic disease in which patients have recurrent inflamed painful nodules, draining sinus tracts and scarring. It can be debilitating for patients and is associated with negative impacts on quality of life. HS is a main research priority for the Skin Investigation Network of Canada. Many areas for further research have been identified, including information about the disease in children and patients of different ethnicities, data on what treatments may work best in different patients, and information gathered in real world settings. We are proposing to create a registry of Canadian patients, including children and adults of all different backgrounds. Our team will include physicians of multiple specialties (dermatology, rheumatology, general surgery; endocrinology) and patients to make sure that we are considering all aspects of the disease and its associations. We will enrol patients in multiple different centres. We will collect information on their HS and other health conditions, as well as treatments and changes over time. We will also include advanced tests of genetics and cytokines to advance understanding of the disease. This data will help us in figuring out how to best treat and manage patients with HS in Canada.

Scientific Summary: Hidradenitis Suppurativa (HS} is a chronic inflammatory disease characterized by recurrent painful nodules, draining sinus tracts, and scarring of intertriginous skin. it can be debilitating for patients and is associated with a considerable burden of disease. The prevalence may be as high as 3.84% in the diverse Canadian population. HS was identified as 1 of the top 10 research priorities by the Skin Investigation Network of Canada. There are numerous questions that this initiative highlighted that need further data to be answered, from pathogenesis to treatment responses. The lack of satisfactory and predictable response to any treatment category underlies ongoing attempts of innumerable medical and surgical therapies, all with reports of efficacy in only some patients. Understanding the different clinical phenotypes .and their associations may help better predict comorbidities and effective treatments across different patient groups and including paediatric populations. There is a need to evaluate these questions in a real­ world setting including the range of diverse patient backgrounds and different clinical phenotypes of HS seen in the Canadian population. Multiple conditions appear to be associated with HS. Optimized care-is provided by multiple specialists, including dermatologists, surgeons, gynaecologists, pain specialists, endocrinologists, dieticians and wound care specialists in addition to family doctors and paediatricians. Several screening recommendations have been published, which may entail considerable time and resources to implement, including up to 20 different comorbidities to be considered. We propose the inception of a Canadian registry of paediatric and adult patients with HS with rich standardized clinical, radiographic, serologic and genetic data. Clinical care templates will ensure screening of important comorbidities and evaluation of the complete range of treatment options for patients. This registry will provide longitudinal data for important knowledge advancement that will address the research questions that have been prioritized by the Skin Investigation Network of Canada.

Goals (Long term): To advance our understanding of the pathogenesis, comorbidities, and lifetime natural history of HS based on a diverse and inclusive Canadian population, and provide all patients with HS a coordinated, individualized and wholistic care to improve clinical outcomes.

Objectives: To create the infrastructure to support a multi-centre registry of patients and ensure coordinated, optimized care of patients with HS in Canada.

Central Hypothesis: A Canadian registry that includes the range of ethnic backgrounds and ages representative of our diverse population will capture important information to advance disease knowledge and outcomes in this population.

Specific Aims:
1. Create a REDCap database to support a registry of patients with HS that will be accessible to practitioners from all three collaborating centres.
2. Create a clinical template that encompasses all the clinical assessments and screening recommendations for initial and follow-up visits for patients with HS, that can be applied at all participating centres

Potential Impact: The registry and clinical template will provide important information to help answer the questions highlighted by the Skin Investigation priority questions. While we will start as a multi­ site initiative within Toronto to build the framework of this collaborative model, we plan to scale to develop a provincial and, eventually, national network including other academic sites across Canada. This will enable us to further capture and enrich data outcomes, as well as include adequately powered cytokine and biomarker analysis to deepen knowledge of HS and address the remaining questions that have been identified by Skin Canada.

Dr. Elena Netchiporouk  (2023 Recipient)

Dr. Elena Netchiporouk is an Assistant Professor in the Divisions of Dermatology and Experimental Medicine at McGill University and a Fonds de Recherche du Québec-Santé (FRQS) Junior 1 Clinician Scientist. She earned her medical degree from the Université de Montréal, completed her dermatology residency at McGill University, and holds an MSc in Experimental Medicine.

Dr. Netchiporouk specializes in complex medical dermatology, orphan diseases, and immune-mediated skin diseases—areas with significant unmet clinical needs and strong patient advocacy. She co-directs several specialty clinics, including the multi-disciplinary urticaria/mastocytosis clinic, the multidisciplinary oncogenodermatology clinic, and the skin fibrosis clinic, where she teaches and mentors dermatology residents and medical students. Since her appointment as a clinician investigator at the Research Institute of the MUHC in 2020, Dr. Netchiporouk dedicates 50% of her time to research. Her current work focuses on the risk factors and pathogenesis of immune-mediated skin diseases and genodermatoses.

Dr. Netchiporouk has published over 145 peer-reviewed articles indexed in PubMed, with an H-index of 29. Her research has been featured in leading dermatology and medical journals, including the Journal of the American Academy of Dermatology, JAMA Dermatology, The Lancet, and The Lancet Americas. Her work is funded by major agencies such as the Canadian Institutes of Health Research (CIHR), Fonds de Recherche du Québec-Santé (FRQS), and Canadian Dermatology Foundation (CDF).

Title: Canadian Morphea Registry (C-MORE): Characterizing the landscape of morphea in Canada and elucidating predictors of severe disease.

Layman Abstract: The Canadian Morphea Registry (C-MORE) is a national research project hosted by the McGill University Health Centre (MUHC) Research Institute. It focuses on localized scleroderma (LS), a rare autoimmune disease that causes skin thickening and can lead to long-term physical and functional complications. C-MORE collects clinical and molecular data from patients across Canada to better understand LS, its prevalence, risk factors, treatment effectiveness, and impact on quality of life. The registry aims to improve diagnosis, guide treatment strategies, and support clinical trials for new therapies. Since 2021, C-MORE has enrolled over 190 patients, created a biobank for research, and developed a network of clinicians and researchers. The goal is to improve care, advance research, and support those living with LS.

Scientific Summary: The Canadian Morphea Registry (C-MORE) is a national research initiative hosted by the McGill University Health Centre Research Institute. It investigates localized scleroderma (LS), an autoimmune disease causing skin fibrosis that can lead to significant functional and aesthetic complications. LS affects approximately 75,000 Canadians and is often diagnosed late, resulting in permanent damage and reduced quality of life. C-MORE addresses critical knowledge gaps in LS by collecting standardized clinical and molecular data. Its goals include studying the disease’s epidemiology, burden, natural history, and treatment outcomes while facilitating clinical trials and improving patient care. Since its launch in 2021, C-MORE has enrolled over 190 patients across eight Canadian sites, established a biobank for translational research, and developed a comprehensive data infrastructure to support national and international collaboration. By bringing together researchers, clinicians, and patients, C-MORE aims to advance understanding of LS, improve treatment strategies, and enhance care for this under-researched autoimmune disease. With SkIN Canada funding for year two, C-MORE will develop a logo, create a website, and establish multi-site REDCap support.

Can SkIN Canada help?

Request support for your study

 

SkIN Canada has launched a formal study intake process for investigators requesting support from the Network. Please visit our  RESOURCES page for more information on how we can help with funding, patient engagement, database creation, project administration, ethics application, or statistical support.

Submit Intake Form 

From the Training Committee Hub

Introducing our Newest Training Committee Member – Davide Brambilla

Dr. Davide Brambilla is associate professor of drug delivery at the Faculty of Pharmacy at the Université de Montreal, Quebec, Canada. Prof. Brambilla completed his PhD in pharmaceutical technologies at the School of Pharmacy of the University of Paris-Sud (now Paris-Saclay) with P Couvreur on the design of nanoparticles for drug delivery applications. In 2012, he joined the Swiss Federal Institute of Technology in Zurich (ETH) where, after 3 years of post-doctoral stay, he was promoted group leader. In 2017, he was appointed Assistant Professor at the Université de Montréal, where he started his research laboratory focused on micro and nanotechnology-based drug delivery tools and diagnostic devices and where he teaches the development of biological drugs and the pharmacokinetics. In 2022 he was appointed associate professor. His laboratory is composed of 12 members and mainly focuses on the design of organic nanoparticles for the delivery of genetic materials for gene therapy applications, and the design of polymeric microneedles for diagnostic applications. He pioneered the concept of fluorescent dermal micro-tattoos for the non-invasive and wearable monitoring of physiological and pathological parameters, which currently investigated clinical settings.
 
He is a junior research fellow of Québec Research Fund, the biotherapy research Chair from the Canadian Generic Pharmaceutical Association and Biosimilars Canada and acts as Editor of the Journal of Controlled Release.‎ In 2023 he was Visiting Professor at the University of Geneva and the Politecnico di Milano. In 2023 he was awarded the new investigator research award of the Association of Faculties of Pharmacy of Canada. He co-authored over 60 publications in peer-reviewed international journals (Sci Adv, Adv Mat, Adv Funct Mat, Small, Biomaterials, J Control Release, JCI Insight), filed 2 patents and co-founded the start-up company mTatt.Inc.

SkIN Canada Travel and Mobility Awards – Application Deadline May 15, 2025

1. Travel Award: The deadline for the next SkIN Canada Trainee Travel Award is Wednesday May 15 (2025) before 11:59 PM ETSkIN Canada provides partial funding for trainees to attend conferences as part of their training experience. A limited number of awards are available each year on a competitive basis. There are two competition periods per year, one in May and one in October. Applicants who have previously received funding through this program in a fiscal year are not eligible to receive funding until the following fiscal year. The value of the SkIN Canada Travel Award is a maximum of $1,000 CAD. 

 

2. Mobility Award: The deadline for the next SkIN Canada Trainee Mobility Award is Tuesday May 15 (2025) before 11:59 PM ETThe SkIN Canada Trainee Mobility Award provides funding for trainees in the field of skin research to study and conduct research for a brief period in a laboratory other than their own within Canada or abroad as part of their training experience. A limited number of awards are available each year on a competitive basis.  There will be two competition periods per year, one in May and one in October. Applicants are eligible for the award only once during a particular training period or level of study (e.g. MSc, PhD, Clinical residency, or Postdoctoral training).
        The value of the Skin Canada Trainee Mobility Award is up to $4,000 which can be used for the trainee’s research in a laboratory other than their own, within Canada or abroad for a period ranging from 2 weeks to 6 months. 

LEARN MORE

 

SkIN Canada Training Committee Opening

The Training Committee represents skin research trainees from across Canada. The Committee considers representations from across Canada to be valuable. The committee currently has an opening for a PhD student or a post-doctoral fellow from any of the Western Provinces. If interested in joining this dynamic committee, please send your expression of interest and CV  to info@skincanada.org.

Next Skin Canada TC meeting: Week of Dec 17, 2024.
Next Skin Canada TC Webinar: Week of March 17, 2025 (Topic: Scleroderma disease mechanisms and recent advances in treatments). 

News from Other Organizations

CIHR New President: Dr. Paul Hébert

Dr. Paul Hébert, a proud Acadian, is a clinician scientist and health leader, as well as a practicing palliative care and former critical care physician. He is a full professor at the University of Ottawa and previously at the Université de Montréal.

As a researcher, he is best known for major resuscitation and transfusion trials. In particular, he led a ground-breaking trial entitled, “Transfusion Requirements in Critical Care (TRICC),” published in the New England Journal of Medicine (1999). This study demonstrated that a restrictive approach to the care of critically ill patients (i.e., giving less blood) was certainly no worse than, and was possibly superior to, giving more red cells. This study decreased blood use in acute care settings worldwide. Many other basic and clinical blood studies followed, including a recent study again published in the NEJM demonstrating that patients suffering from an myocardial infarction are one of the only patients who need more blood rather than less.

Dr. Hébert has conducted research in both critically ill adults and children, palliative care, aging in place and long term care. To do so, he secured over $65 million in research project funding. These investments have resulted in excess of 480 articles in peer reviewed journals (16 articles in NEJM, 13 in the Journal of the American Medical Association, 3 in the Lancet, 7 in the Annals of Internal Medicine, and 9 in the British Medical Journal). These projects and publications would not have been possible without the support of the Canadian Critical Trials Group, the help and support of literally thousands of patients and families, nurses, physicians and researchers from around the globe. He is most proud of the young faculty from several universities that he has had the pleasure of mentoring, from whom he has learned a great deal.

During his career, he has had the opportunity to be the Canadian Medical Association’s Editor-in-Chief, publishing over 80 editorials in Canada’s leading medical journal, chaired the Canadian Critical Care Trials Group, the world top critical care research network, mounting major programs and leading more than 400 physicians as a Physician-in-Chief and Director of clinical research at the Centre de Recherche du Centre hospitalier de l’Université de Montréal ; the Chief Medical and Science Officer at the Canadian Red Cross and a scientific Director of Ontario’s Public Health Emergency taskforce. These many leadership experiences have provided him with unique and diverse perspectives on the health care and health research ecosystems.

Dr. Hébert has had a long relationship with the former Medical Research Council and now with CIHR, and he attributes much of his success to funding from MRC/CIHR. Dr. Hébert has led a clinical trial transformation initiative for MRC, was a member of an inaugural Institute Advisory Board, been on many peer review panels and developed the vision for the Strategy for Patient-Oriented Research as its original Executive Director. Dr. Hébert is a Fellow of the Canadian Academies of Health Science, and was also the recipient of a number of career awards including the Landsteiner-Alter award for his groundbreaking work in transfusion medicine.

CIHR-IMHA Funding Opportunities

Notice of upcoming funding opportunity: Catalyst Grants in Oral Health Data Analysis

The Canadian Institutes of Health Research (CIHR) is pleased to announce the upcoming launch of the Catalyst Grants in Oral Health Data Analysis. This funding opportunity is a collaboration between the Institute of Musculoskeletal Health and Arthritis and the Institute of Aging and will fund targeted analysis of the Oral Health Component (OHC) of the Canadian Health Measures Survey (CHMS) Cycle 7 data.

 

A note from Dana Gies,  Executive Director CSPA.

We are excited to announce that registration for our Breaking Barriers virtual symposium is now open! Our theme is Bolstering mental health & resiliency among skin patients, and we have some phenomenal speakers and discussions planned for you. We encourage all patients and caregivers to join us for these informative and inspiring sessions on Dec. 4th and 5th: https://bit.ly/breaking-barriers-2024.
We also want to take a moment to appreciate the friends and family members in your lives and in the lives of patients across Canada who go above and beyond in supporting people impacted by skin, hair and nail conditions. We recognize the time and energy that loved ones dedicate to supporting people living with diverse health conditions, and to celebrate these often unsung efforts, we’d love to hear their story and have them nominated for the Tanny Nadon Caregiver Award. To nominate a loved one today and learn more about the award and the Spotlight series, you can visit our website: https://canadianskin.ca/get-involved/patients-and-caregivers/tanny-nadon-caregiver-award.

Best regards, 

Dana Gies

Recent Publications on Skin Research
Inflammatory Skin Conditions
 

1.    Arora P, Brumley C, Arrington K, Hylwa S. Allergic Contact Dermatitis in Skin of Color: A Retrospective Study from a Comprehensive Patch Testing Center. Dermatitis. Sep 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39308405
2.    Kearns-Turcotte S, McCuaig C, Powell J, Piram M, Marcoux D, Hatami A, Coulombe J. Pediatric BASCULE syndrome in 42 patients: a peek into dysautonomia. J Am Acad Dermatol. Sep 21 2024.https://www.ncbi.nlm.nih.gov/pubmed/39313031
3.    Caucheteux SM, Piguet V. Hidradenitis Suppurativa Tunnels Invasive Transcriptional Signature. The Journal of investigative dermatology. Sep 24 2024.https://www.ncbi.nlm.nih.gov/pubmed/39320303
4.    Savinova I, Gooderham M, O’Toole A, Cy A, Bawazir M, Abu-Hilal M. Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study. J Cutan Med Surg. Sep 25 2024:12034754241287553.https://www.ncbi.nlm.nih.gov/pubmed/39323064
5.    Chu AWL, Rayner DG, Chu X, Chen L, Dong AYH, Waserman S, Baker DR, Sheikh J, Moellman J, Lang DM, Ben-Shoshan M, Mathur SK, Beck LA, Khan DA, Oliver ET, Asiniwasis RN, Chan J, Cole EF, Trayes KP, Frazier WT, Runyon L, Wheeler KE, Eftekhari S, Gardner DD, Winders T, Bernstein JA, Saini SS, Chu DK. Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. Oct 2024;133(4):437-444 e418.https://www.ncbi.nlm.nih.gov/pubmed/38901542

READ MORE

 

Wound Healing, Fibrosis and Regeneration

1.    Safoine M, Paquette C, Gingras GM, Fradette J. Improving Cutaneous Wound Healing in Diabetic Mice Using Naturally Derived Tissue-Engineered Biological Dressings Produced under Serum-Free Conditions. Stem Cells Int. 2024;2024:3601101.https://www.ncbi.nlm.nih.gov/pubmed/38737365
2.    Rijal H, Bouadi N, Piguet V, Mukovozov I. Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review. J Cutan Med Surg. Jun 10 2024:12034754241260021.https://www.ncbi.nlm.nih.gov/pubmed/38859662
3.    Arif S, Richer M, Larochelle S, Moulin VJ. Microvesicles derived from dermal myofibroblasts modify the integrity of the blood and lymphatic barriers using distinct endocytosis pathways. J Extracell Biol. May 2024;3(5):e151.https://www.ncbi.nlm.nih.gov/pubmed/38939570
4.    Arif S, Larochelle S, Trudel B, Gounou C, Bordeleau F, Brisson AR, Moulin VJ. The diffusion of normal skin wound myofibroblast-derived microvesicles differs according to matrix composition. J Extracell Biol. Jan 2024;3(1):e131.https://www.ncbi.nlm.nih.gov/pubmed/38938680
5.    Yang Y, Gomez N, Infarinato N, Adam RC, Sribour M, Baek I, Laurin M, Fuchs E. The pioneer factor SOX9 competes for epigenetic factors to switch stem cell fates. Nature cell biology. Jul 24 2023.https://www.ncbi.nlm.nih.gov/pubmed/37488435

READ MORE

 


Skin Cancer

1.    Zvulunov A, Neale H, Stern J, Santaguida P, Stein AB, Koh M, Eichenfield LF, Guitart J, Goebeler M, Scarisbrick J, Willemze R, Coughlin CC, George R, Brazzelli V, Marschalko M, Belousova I, Querfeld C, Bagot M, Szepietowski JC, Papadavid E, Quaglino P, Hoeger P, Ortiz-Romero PL, Nikolaou V, Dummer R, Aung PP, Lawley L, Morel KD, Ngan B, Wain M, Gameiro A, Lacy-Niebla RM, Pope E. Approach to Mycosis Fungoides in children (ARMFUL study): consensus-based recommendations. J Am Acad Dermatol. Aug 22 2024.https://www.ncbi.nlm.nih.gov/pubmed/39181404
2.    Weir VR, Dempsey K, Gichoya JW, Rotemberg V, Wong AI. A survey of skin tone assessment in prospective research. NPJ Digit Med. Jul 17 2024;7(1):191.https://www.ncbi.nlm.nih.gov/pubmed/39014060
3.    Negbenebor NA. Championing Diversity in Mohs and Cutaneous Oncology: Reducing Disparities in Skin Cancer Care for Patients of Color. Am Soc Clin Oncol Educ Book. Jun 1 2024;44(3):e433376.https://www.ncbi.nlm.nih.gov/pubmed/39013125
4.    Narod SA, Metcalfe K, Finch A, Chan AW, Armel SR, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Foulkes WD, Neuhausen SL, Eng C, Olopade O, Zakalik D, Couch F, Cullinane C, Pal T, Sun P, Kotsopoulos J, Hereditary Breast Cancer Clinical Research G. The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations. Hered Cancer Clin Pract. May 13 2024;22(1):7.https://www.ncbi.nlm.nih.gov/pubmed/38741145
5.    Ituarte BE, Taylor MA, Thomas SI, Ehsan E, Griffin J, Fernandez JM, Wei EX. Analysis of increasing prevalence of skin of colour publications in the PubMed database. J Eur Acad Dermatol Venereol. May 11 2024.https://www.ncbi.nlm.nih.gov/pubmed/38733280

READ MORE

 

 

Skin of Colour

1.    Yasnova N, Sirait SP, Rahmayunita G. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial. Acta Dermatovenerol Alp Pannonica Adriat. Jun 2024;33(2):83-88.https://www.ncbi.nlm.nih.gov/pubmed/38918942
2.    Yang LJ, Kundu RV. Differences in attitudes toward aging skin between skin of color and non-skin of color consumers: A cross-sectional survey study. JAAD Int. Sep 2024;16:201-203.https://www.ncbi.nlm.nih.gov/pubmed/39040840
3.    Xue GR, Hamzavi IH, Kohli I, Mohammad TF. Challenges of tinted sunscreen in skin of color. Int J Dermatol. Sep 2024;63(9):e221-e222.https://www.ncbi.nlm.nih.gov/pubmed/39215428
4.    Woolery-Lloyd HC. INDIVIDUAL ARTICLE: Skincare in Skin of Color: A Comprehensive Approach to Preprocedure, Intraprocedure, and Postprocedure. J Drugs Dermatol. Aug 1 2024;23(8):62041s62045-62041s62010.https://www.ncbi.nlm.nih.gov/pubmed/39093664
5.    Williams K, Yaldo M, Olds H, Moossavi M. A large exophytic plaque on the shoulder of a skin of color patient. Int J Dermatol. Apr 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38572509

 
 
Other

1.    Savard E, Magne B, Simard-Bisson C, Martel C, Larouche D, Gauvin R, Moulin VJ, Germain L. Design of an innovative method for measuring the contractile behaviour of engineered tissues. Tissue engineering. Part C, Methods. Sep 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39311467
2.    Richardson KC, Jung K, Matsubara JA, Choy JC, Granville DJ. Granzyme B in aging and age-related pathologies. Trends in molecular medicine. Aug 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39181801
3.    Rayner DG, Liu M, Chu AWL, Chu X, Guyatt GH, Oykhman P, Cao DJ, Moellman J, Ben-Shoshan M, Baker DR, Waserman S, Lang D, Sheikh J, Mathur SK, Beck LA, Khan DA, Oliver ET, Asiniwasis RN, Cole EF, Wheeler KE, Runyon L, Chan J, Trayes KP, Eftekhari S, Gardner DD, Winders T, Saini SS, Bernstein J, Chu DK. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: a systematic review and meta-analysis of randomized clinical trials. The Journal of allergy and clinical immunology. Jun 7 2024.https://www.ncbi.nlm.nih.gov/pubmed/38852861
4.    McDermid A, Lam K, Ko YCK, Schmitt T, Khosravi-Hafshejani T, Dutz JP. Cyclosporin als Erstlinienbehandlung bei SARS‐CoV‐2‐reaktiver infektiöser mukokutaner Eruption bei Erwachsenen. J Dtsch Dermatol Ges. Jul 2024;22(7):1013-1015.https://www.ncbi.nlm.nih.gov/pubmed/38978425
5.    McDermid A, Lam K, Ko YCK, Schmitt T, Khosravi-Hafshejani T, Dutz JP. SARS-CoV-2 reactive infectious mucocutaneous eruptions in adults treated with cyclosporine as first line treatment. J Dtsch Dermatol Ges. Jun 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38837589


READ MORE

 

SkIN Canada Executive Committee